Pharmaceutical care for immune-related adverse events induced by toripalimab

doi:10.19803/j.1672-8629.20230428

Abstract

Abstract: Objective To explore the pharmaceutical care approach of clinical pharmacists in immune-related adverse events caused by toripalimab. Methods A clinical pharmacist conducted a pharmacy checkup on a case in which renal injury, hypothyroidism and skeletal muscle toxicity were detected in a patient treated with toripalimab, and determined that the patient was most likely to have adverse reactions caused by toripalimab through the evaluation of the correlation of the adverse reactions and the analysis of the mechanism. Results A clinical pharmacist assisted the physician in formulating the treatment plan, and conducted full-scale pharmacological monitoring of the patient, achieving good results. Conclusion Clinical pharmacists play an important role in the identification and management of immune-related adverse events, effectively ensure the safety of medication.

Key words: toripalimab, renal injury, hypothyroidism, skeletal muscle toxicity, rhabdomyolysis, adverse drug reaction(ADR), pharmaceutical care

CLC Number:

R994.11

JI Qiuxia, JIN Jian, ZHANG Bin. Pharmaceutical care for immune-related adverse events induced by toripalimab[J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 346-348.

Add to citation manager EndNote|Ris|BibTeX

URL: https://www.zgywjj.com/EN/10.19803/j.1672-8629.20230428

https://www.zgywjj.com/EN/Y2024/V21/I3/346

References

[1] CHOW LQM, HADDAD R, GUPTA S, et al.Antitumor activity of pembolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib keynote-012 expansion cohort[J]. J Clin Oncol, 2016, 34(32): 3838-3845.
[2] ZHANG L, HAO B, GENG Z, et al.Toripalimab: the first domestic anti-tumor PD-1 antibody in China[J]. Front Immunol, 2022 (1): 730666.
[3] WU Q, ZHANG S, HUA X, et al.Complete and enduring response in an elderly patient with repeated recurrent gingival squamous cell carcinoma treated by combined toripalimab and single agent chemotherapy: a case report[J]. Ann Palliat Med, 2021, 10(6): 6968-6973.
[4] BARAIBAR I, MELERO I, PONZ-SARVISE M, et al.Safety and tolerability of immune checkpoint inhibitors (PD-1 and PD-L1) in cancer[J]. Drug Saf, 2019, 42(2): 281-294.
[5] WANG ND, DING ZY, ZHAO QC, et al.Pharmaceutical monitoring of a patient with multiple immune-related adverse events after treatment with triprilizumab[J]. Practical Pharmacy & Clinical Remedies(实用药物与临床), 2023, 26(3): 233-236.
[6] CHEN Y, CHEN Y, XIE J, et al.Multisystem immune-related adverse events due to toripalimab: Two cases-based review[J]. Front Cardiovasc Med, 2022, 9(11): 1036603.
[7] KODA R, WATANABE H, TRUCHIDA M, et al.Immune checkpoint inhibitor(nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis:A case report[J]. BMC Nephrol, 2018, 19(1): 48.
[8] SHIMAMURA Y, WATANABE S, MAEDA T, et al . Incidence and risk factors of acute kidney injury, and its effect on mortality among Japanese patients receiving immune check point inhibitors: A single-center observational study[J]. Clinical and Experimental Nephrology, 2021, 25(5): 479-487.
[9] LI L, LI G, RAO B, et al.Landscape of immune checkpoint inhibitor-related adverse events in Chinese population[J]. Scientific Reports, 2020, 10(1): 15567.
[10] MORGANSTEIN DL,LAI Z,SPAIN L,et al.Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treat-ment of melanoma[J]. Clin Endocrinol (Oxf), 2017, 86(4): 614-602.
[11] JOHNSON DB, BALKO JM, COMPTON ML, et al.Fulminant myocarditis with combination immune checkpoint blockade[J]. N Engl J Med, 2016, 375(18): 1749-1755.
[12] HUANG L.The analysis of clinical characteristics in 30 patients with hypothyroidism and muscular damage[D]. Jinan: Shandong University,2017.
[13] Guidelines Working Committee of Chinese Society of Clinical Oncology. Chinese Society of Clinical Oncology (CSCO) immune checkpoint inhibitor-related toxicity management guidelines[中国临床肿瘤学会(CSCO) 免疫检查点抑制剂相关的毒性管理指南] [M]. Beijing: People’s Medical Publishing House, 2019.
[14] Chinese Society of Endocrinology. Guidelines for the diagnosis and treatment of hypothyroidism in adults[J]. Chinese Journal of Endocrinology and Metabolism(中华内分泌代谢杂志),2017,33(2): 167-180.
[15] Immune-endocrinology Group, Chinese Society of Endocrinology Chinese Medical Association.Chinese expert consensus on the immune checkpoint inhibitors-induced endocrine immune-related adverse events(2020)[J]. Chinese Journal of Endocrinology and Metabolism(中华内分泌代谢杂志),2021, 37(1): 1-16.
[16] GU SL.The effect and mechanism on regeneration and repair in renal tubular epithelial cell after injury by the inhibitory proliferation effect of ACEI and ARB[D]. Fuzhou: Fujian Medical University, 2014.
[17] Chinese Society of Nephrology, Renal Diseases Committee of the Chinese. Society of Integrative Medicine. Guidelines for the management of renal hypertension in China 2016[J]. Chinese Society of Nephrology, 2017, 97(20): 1547-1555.
[18] LI YD.Treatment of diabetic nephropathy with calcitriol: A Meta-analysis[D]. Changchun: Jilin University, 2017.
[19] MOREIRA A, LOQUAI C, PFÖHLER C, et al. Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors[J]. Eur J Cancer, 2019, 106(1): 12-23.
[20] SZNOL M, POSTOW MA, DAVIES MJ, et al.Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management[J]. Cancer Treat Rev, 2017, 58(7): 70-76.
[21] WANG XM, WANG WJ, WANG XH, et al.Application of the patient report form about Immune-related adverse events in the treatment of pd-1 inhibitors[J]. Clinical Journal of Traditional Chinese Medicine(中医药临床杂志), 2020, 32(1): 159-163.